| HOME >> BIOLOGY >> TECHNOLOGY |
- ipamorelin, for the i.v. treatment of post operative ileus, the impairment of bowel motility following surgery, an unmet medical need (Phase II);
- ST-1141, a new oral compound, for the treatment of opioid-induced bowel dysfunction (Phase I);
- Other products at research stage.
The acquisition will have a direct, positive impact on the Helsinn Group since the production of Helsinn Therapeutics (US) Inc. products will be manufactured in Helsinn's high standard quality manufacturing facilities in Switzerland which operate according to EU and FDA health and environmental requirements.
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland. Helsinn's unique business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Group in-licenses early stage new chemical entities, completes their development from the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC) development, to the filing for and attainment of their market approval worldwide.
Helsinn's products are sold directly, through the Group subsidiaries, or eventually out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.
The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn's cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers.
Helsinn is the worldwide licensor of palonosetron, a second generation
5-HT3 r
'/>"/>
| SOURCE Helsinn Healthcare SA Copyright©2009 PR Newswire. All rights reserved |